What makes MDLinx Internal Medicine different from all the other primary care literature reviews? Our team of medical editors read over 2,000 medical journals every day so you can stay current in less than 5 minutes! They sort, rank and summarize every article that will impact your daily practice. They even mark which articles are available in free full text, which are clinical or evidence-based, and which have MDLinx Exclusive Author Commentary from the people who actually performed the research.
Also on this page you’ll see bonus content from our physician editor, D. Scott Cunningham, MD, PhD, in the form of his top highlights you can’t miss, along with clinical pearls from The Smartest Internist, a quiz competition from the editors of MDLinx Internal Medicine in collaboration with the Cleveland Clinic Center for Continuing Education.
Your Unread Messages in Internal Medicine
See All >> Messages include industry-sponsored communications and special communications from MDLinx
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Outcome in MI patients with hyponatremia
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage
Smartest Doc Challenge
MDLinx
Clinical Pearls for Hospitalists
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
221 Enterococcus faecalis Infective Endocarditis Circulation, May 2, 2013 Clinical Article
222 A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (coral) study Full Text European Urology, May 2, 2013 Clinical Article
223 Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors Clinical Cancer Research, May 2, 2013 Clinical Article
224 Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK British Journal of Cancer, May 2, 2013 Clinical Article
225 A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Efficacy, Safety, and Tolerability of Naloxegol in Patients With Opioid-induced Constipation Pain, May 2, 2013 Clinical Article
226 Statin use in relation to prostate cancer outcomes in a population-based patient cohort study The Prostate, May 2, 2013 Clinical Article
227 Effectiveness of antidementia drugs in delaying Alzheimers disease progression Alzheimer's & Dementia, May 2, 2013 Clinical Article
228 The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance Digestive Diseases and Sciences, May 2, 2013 Clinical Article
229 Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors Cancer Chemotherapy and Pharmacology, May 2, 2013 Clinical Article
230 Pharmacokinetics and Pharmacodynamics of Ponesimod, a Selective S1P1 Receptor Modulator, in the First-in-Human Study. British Journal of Clinical Pharmacology, May 2, 2013 Clinical Article
231 Degradation of Stored Movement Representations in the Parkinsonian Brain and the Impact of Levodopa Neuropsychologia, May 2, 2013 Clinical Article
232 Long-term effectiveness of acetazolamide on permanent weakness in hyperkalemic periodic paralysis Neuromuscular Disorders, May 2, 2013
233 Effects of levetiracetam on mu rhythm in persons with epilepsy Journal of Clinical Neuroscience, May 2, 2013 Clinical Article
234 The effect of transdermal opioid use on breakthrough opioid and sedative prescribing for rural patients with chronic pain in Northwest Tasmania: a longitudinal study Full Text Journal of Pain Research, May 2, 2013 Clinical Article
235 2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy High Blood Pressure & Cardiovascular Prevention, May 2, 2013 Clinical Guideline
236 Oral Contraceptives Do Not Affect Muscle Strength and Hop Performance in Active Women Clinical Journal of Sport Medicine, May 2, 2013 Evidence Based Medicine Clinical Article
237 Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, and Famotidine: A Prospective, Randomized, Crossover Study Full Text Clinical Cardiology, May 1, 2013 Clinical Article
238 Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-l) Diabetes Care, May 1, 2013 Clinical Article
239 Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial Coronary Artery Disease, May 1, 2013 Clinical Article
240 Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection Clinical Gastroenterology and Hepatology , May 1, 2013 Clinical Article
Among 130 patients requiring mechanical ventilation, 107 were vitamin D-deficient (< 20 ng/ml). Of the patients who did not survive, the length of survival was shorter in the vitamin D-deficient patients (15.3 vs. 24.2 days, respectively).
Read the article summaryResearchers at Tel-Aviv University have conducted a study to determine the value of coronary artery calcium (CAC) measurements in cardiovascular risk stratification in patients with T2DM and HTN. The study involved 423 patients enrolled in the International Nifedipine Study: Intervention as Goal for Hypertension Therapy. The patients had baseline CT scans for CAC measurement at baseline and were shown to be free of disease. Follow-up CT scans were performed at 3 and 15 years. Cardiovascular events (CVEs) occurred in 41 of 423 patients at 3 years and 111 of 268 patients at 15 years of follow-up. CVEs occurred in 15% and 52% (CAC+) and 7% and 32% (CAC-) of patients with T2DM at 3 and 15 years of follow-up, respectively. Compared to patients without T2DM and no CAC, the HRs for a CVE were 6.6 and 3.9 in T2DM patients with and without CAC, respectively.
Read the article summaryResearchers at Erasmus University Medical Center in Rotterdam have evaluated 12 measures (N-terminal fragment of prohormone B-type natriuretic peptide levels, von Willebrand factor antigen levels, fibrinogen levels, chronic kidney disease, leukocyte count, C-reactive protein levels, homocysteine levels, uric acid levels, coronary artery calcium [CAC] scores, carotid intima–media thickness, peripheral arterial disease, and pulse wave velocity), in addition to Framingham risk scores for predicting coronary heart disease. Only the CAC was shown to add significantly to the Framingham risk score in predicting coronary heart disease.
Read the article summaryIndexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicine more
Register now to view all the MDLinx contents (FREE)!
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close